The FDA’s “Operation Warp Speed” equivalent for rare disease will include programs from Denali Therapeutics, Neurogene, Larimar Therapeutics and Grace Science, the companies announced June 3 in separate press releases.
Grace Science, LLC Selected by FDA to Participate in the START Pilot Program for GS-100 Gene Therapy for NGLY1 Deficiency and Announcement of the Successful Treatment of the 2nd Patient
Grace Science Announces First Patient Treated in Phase 1/2/3 Trial of GS-100
Grace Announces Clearance of IND to Initiate a Phase 1/2/3 Trial of AAV9 NGLY1